An Update on Senolytics Company Cleara Biotech

Senescent cells accumulate with age, and that accumulation is responsible for a meaningful fraction of degenerative aging. Many groups are working on ways to remove these cells and thereby reverse aspects of aging. Among their number, Cleara Biotech was founded four years ago on to advance initially promising work on the FOXO4-p53 interaction in cellular senescence, a possible targeted way to destroy senescent cells. This approach will join the numerous other mechanisms already being exploited as the basis for potential rejuvenation therapies. A couple of companies have been looking into FOXO4 biochemistry in the context of cellular senescence, with very little new information emerging in recent years. Four years isn't that long in the biotech field, in which every aspect of development is challenging, but silence suggests that making something of the early FOXO4-related research has proved to be harder than expected. Still, the Cleara principals appear confident enough in their present approach to be gearing up to prepare for clinical development. Certainly, there will be room for many different approaches and specializations in the clearance of senescent cells; it is coming to be a crowded field of many biotech startups and other entities pursing a diverse set of approaches and development programs. Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases Cleara Biotech...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs